Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- New Molecular Target-based Therapeutics for Lung Cancer Presented: AstraZeneca Seminar
October 29, 2001
- WORLD NEWS IN BRIEF
October 29, 2001
- Overseas Business Strategy of Domestic Firms Focused on:PMSRL Seminar
October 29, 2001
- Chugai Licenses in Polyglutamate Paclitaxel from CTI Technologies
October 29, 2001
- Meiji Seika to Codevelop Antibiotics with Kosan Biosciences in US
October 29, 2001
- Kowa, Novartis to Comarket Hypadil Kowa Ophthalmic Solution
October 29, 2001
- 60th Annual Meeting of the Japanese Cancer Association
October 29, 2001
- Companies' Interest in Pharmacoeconomics Data Has Declined
October 29, 2001
- Administration of Statins to the Elderly Recommended: Results of PATE Study
October 29, 2001
- Taisho Tanabe Pharma Group to Focus on Ethical Drugs: Tanabe President
October 29, 2001
- Simvastatin Inhibits Coronary Arteriosclerosis: JUST Study
October 29, 2001
- BUSINESS NEWS IN BRIEF
October 29, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
October 29, 2001
- Drug Cost Ratio Down to 16.8% of Medical Cost for Outpatients in 1998
October 29, 2001
- Olympus Codevelops Ultrasound Surgical System with Intuitive Surgical of the US
October 29, 2001
- Glivec Recommended for Approval
October 29, 2001
- GEYMS Markets Fully-digital Ultrasound Diagnostic Equipment
October 29, 2001
- Dr Takemi, Lawmaker, Strongly Opposes Korosho, MOF Reform Plans
October 29, 2001
- Toshiba, NTT Com to Start ASP Services for Remote Imaging Diagnosis
October 29, 2001
- Korosho's NHI Price System Reform Is Full of Contradictions: Mr Yashiro of FPMAJ
October 29, 2001
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…